Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Cash & Equivalents (2016 - 2025)

Anaptysbio's Cash & Equivalents history spans 10 years, with the latest figure at $238.2 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 93.53% year-over-year to $238.2 million; the TTM value through Dec 2025 reached $238.2 million, up 93.53%, while the annual FY2025 figure was $238.2 million, 93.53% up from the prior year.
  • Cash & Equivalents reached $238.2 million in Q4 2025 per ANAB's latest filing, up from $109.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $495.7 million in Q4 2021 to a low of $26.3 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $147.0 million, with a median of $96.6 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: plummeted 85.62% in 2022, then surged 628.58% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $495.7 million in 2021, then tumbled by 85.62% to $71.3 million in 2022, then tumbled by 49.56% to $36.0 million in 2023, then soared by 242.22% to $123.1 million in 2024, then soared by 93.53% to $238.2 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Cash & Equivalents are $238.2 million (Q4 2025), $109.8 million (Q3 2025), and $44.3 million (Q2 2025).